Dr. Socoteanu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1300 N 4th St
Longview, TX 75601Phone+1 903-757-2122Fax+1 903-757-9475
Summary
- Dr. Matei Socoteanu is an experienced Oncologist based in Longview, TX. He obtained his medical degree from LSU School of Medicine in Shreveport in 2004 and completed his internship and residency at the University of Tennessee Medical Center at Knoxville. He also completed a fellowship concentrating on Hematology and Medical Oncology at Texas A&M College of Medicine. Dr. Socoteanu specializes in general medical oncology, has contributed to multiple publications, and has been cited by other publications multiple times. Highlights include his works on Metastatic NSCLC and Squamous Non-Small-Cell Lung Cancer. He has conducted clinical trials, notably one involving Brentuximab Vedotin to treat Hodgkin Lymphoma and CD30-expressing Peripheral T-cell Lymphoma. Dr. Socoteanu was awarded the Meaningful Use Stage 1 Certification from Centers for Medicare & Medicaid Services in 2012.
Education & Training
- Texas A&M College of Medicine-Scott and White Medical Center (Temple)Fellowship, Hematology and Medical Oncology, 2009
- University of Tennessee Medical Center at KnoxvilleResidency, Internal Medicine, 2004 - 2007
- University of Tennessee Medical Center at KnoxvilleInternship, Internal Medicine, 2004 - 2005
- LSU School of Medicine in ShreveportClass of 2004
Certifications & Licensure
- TX State Medical License 2008 - 2026
- TN State Medical License 2006 - 2008
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
Publications & Presentations
PubMed
- 29 citationsRandomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)David R. Spigel, Robert M. Jotte, John Nemunaitis, Merrill Kingman Shum, Jeffrey A. Schneider
Journal of Thoracic Oncology. 2021-02-01 - 8 citationsnab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC.Corey J. Langer, Edward S. Kim, Eric C. Anderson, Robert M. Jotte, Manuel Modiano
Frontiers in Oncology. 2018-07-24 - 30 citationsc-Met targeted therapy of cholangiocarcinoma.Matei P. Socoteanu, Frank E. Mott, Gianfranco Alpini, Arthur E. Frankel
World Journal of Gastroenterology. 2008-05-21
Research History
- Director of Research Longview Cancer Center2010 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: